Other Content - BioPharm International


Other Content

Report from Taiwan

June 1, 2013

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

Johnson & Johnson's Pharma Sector Poised for Growth, 10 New Product Filings Expected by 2017

May 28, 2013

Johnson & Johnson anticipates submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017; the announcement was made at a recent meeting with industry analysts. Upcoming new products include simeprevir for hepatitis C (already filed in Japan, Europe and the US); ibrutinib and daratumumab for haematologic malignancies; sirukumab and guselkumab for diseases of the immune system such as rheumatoid arthritis and psoriasis; and vaccines for influenza, rabies and polio.

US Government Signs Deal with GSK to Develop Antibiotics

May 23, 2013

Partnership will support development of drugs to fight antibiotic resistance and bioterrorism.

USP Offers Herbal Medicines Compendium

May 20, 2013

The U.S. Pharmacopeial Convention is offering free online access to public standards to help ensure the quality of the herbal ingredients used in medicinal products.

Actavis to Acquire Warner Chilcott

May 20, 2013

Actavis Inc. and Warner Chilcott plc have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion.

Legislation to Protect Subjects in Clinical Trials Introduced

May 16, 2013

Legislation designed to protect clinical trial study participants, close loopholes, and bring certainty and public transparency to research studies, has been introduced.

Report Previews Future of U.S. Biosimilar Market

May 15, 2013

Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.

Amgen Forms New Joint Venture to Commercialize Vectibix in China

May 13, 2013

Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor (EGFR) antibody approved by FDA for the treatment of metastatic colorectal cancer.

Tamiflu Leads Q1 Drug Sales Growth

May 7, 2013

In the first quarter of 2013, the rankings for the top five drugs by sales shifted a bit, but exhibited positive growth for the quarter.



Click here